Genmab A/S (GMAB) - Total Liabilities
Based on the latest financial reports, Genmab A/S (GMAB) has total liabilities worth Dkr1.27 Billion DKK (≈ $198.70 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Genmab A/S's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Genmab A/S - Total Liabilities Trend (2002–2024)
This chart illustrates how Genmab A/S's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Genmab A/S.
Genmab A/S Competitors by Total Liabilities
The table below lists competitors of Genmab A/S ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hua Nan Financial Holdings Co Ltd
TW:2880
|
Taiwan | NT$4.30 Trillion |
|
Curtiss-Wright Corporation
NYSE:CW
|
USA | $2.69 Billion |
|
China Tungsten and Hightech Materials Co Ltd
SHE:000657
|
China | CN¥16.94 Billion |
|
Synnex Corporation
NYSE:SNX
|
USA | $29.56 Billion |
|
Roku Inc
NASDAQ:ROKU
|
USA | $1.75 Billion |
|
CMS Energy Corporation
NYSE:CMS
|
USA | $30.71 Billion |
|
Cerebras Systems Inc. Class A Common Stock
NASDAQ:CBRS
|
USA | $2.47 Billion |
|
CyberArk Software Ltd
NASDAQ:CYBR
|
USA | $2.41 Billion |
Liability Composition Analysis (2002–2024)
This chart breaks down Genmab A/S's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Genmab A/S to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genmab A/S's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genmab A/S (2002–2024)
The table below shows the annual total liabilities of Genmab A/S from 2002 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Dkr9.11 Billion ≈ $1.43 Billion |
+147.73% |
| 2023-12-31 | Dkr3.68 Billion ≈ $575.61 Million |
+29.68% |
| 2022-12-31 | Dkr2.84 Billion ≈ $443.87 Million |
+16.70% |
| 2021-12-31 | Dkr2.43 Billion ≈ $380.35 Million |
+20.23% |
| 2020-12-31 | Dkr2.02 Billion ≈ $316.36 Million |
+84.49% |
| 2019-12-31 | Dkr1.10 Billion ≈ $171.48 Million |
+145.39% |
| 2018-12-31 | Dkr446.64 Million ≈ $69.88 Million |
+35.04% |
| 2017-12-31 | Dkr330.75 Million ≈ $51.75 Million |
-19.63% |
| 2016-12-31 | Dkr411.54 Million ≈ $64.39 Million |
-1.03% |
| 2015-12-31 | Dkr415.83 Million ≈ $65.06 Million |
-50.13% |
| 2014-12-31 | Dkr833.74 Million ≈ $130.45 Million |
-22.23% |
| 2013-12-31 | Dkr1.07 Billion ≈ $167.72 Million |
-18.15% |
| 2012-12-31 | Dkr1.31 Billion ≈ $204.91 Million |
+21.49% |
| 2011-12-31 | Dkr1.08 Billion ≈ $168.66 Million |
-23.08% |
| 2010-12-31 | Dkr1.40 Billion ≈ $219.28 Million |
+51.63% |
| 2009-12-31 | Dkr924.34 Million ≈ $144.62 Million |
-13.64% |
| 2008-12-31 | Dkr1.07 Billion ≈ $167.47 Million |
-0.48% |
| 2007-12-31 | Dkr1.08 Billion ≈ $168.27 Million |
+445.81% |
| 2006-12-31 | Dkr197.05 Million ≈ $30.83 Million |
-21.70% |
| 2005-12-31 | Dkr251.66 Million ≈ $39.37 Million |
+176.79% |
| 2004-12-31 | Dkr90.92 Million ≈ $14.23 Million |
-2.94% |
| 2003-12-31 | Dkr93.67 Million ≈ $14.66 Million |
-49.08% |
| 2002-12-31 | Dkr183.97 Million ≈ $28.78 Million |
-- |
About Genmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervic… Read more